- AU$21.64m
- AU$5.26m
- AU$1.80m
- 48
- 28
- 43
- 36
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.23 | ||
| Price to Tang. Book | 1.23 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.05 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -23.15% | ||
| Return on Equity | -20.01% | ||
| Operating Margin | -114.29% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 2.39 | 2.52 | 0.15 | 0.77 | 1.8 | n/a | n/a | -13.34% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.
Directors
- Roger Aston NEC
- Jerry Kanellos COO
- Dan Peres OTH
- Phillip Hains SEC
- Ravi Savarirayan DRC
- Stephen Anastasiou NED
- Daniel Pollock NED
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 13th, 1994
- Public Since
- April 30th, 1999
- No. of Employees
- 6
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 227,798,346
- Address
- L 3 62 Lygon St, MELBOURNE, 3053
- Web
- https://www.immuron.com.au
- Phone
- +61 398245254
- Auditors
- Grant Thornton Audit Pty Ltd
Upcoming Events for IMC
Half Year 2025 Immuron Ltd Earnings Release
Similar to IMC
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Anatara Lifesciences
Australian Stock Exchange - SEATS
Argent BioPharma
Australian Stock Exchange - SEATS
FAQ
What is the Immuron share price?
As of Today at 21:16 UTC, shares in Immuron are trading at AU$0.10. This share price information is delayed by 15 minutes.
How has the Immuron share price performed this year?
Shares in Immuron last closed at AU$0.10 and the price had moved by +28.38% over the past 365 days. In terms of relative price strength the Immuron share price has outperformed the ASX All Ordinaries Index by +15.78% over the past year.
What are the analyst and broker recommendations for Immuron?
There is no consensus recommendation for this security.
Find out moreWhat is the Immuron dividend yield?
Immuron does not currently pay a dividend.
Does Immuron pay a dividend?
Immuron does not currently pay a dividend.
When does Immuron next pay dividends?
Immuron does not currently pay a dividend.
How do I buy Immuron shares?
To buy shares in Immuron you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Immuron?
As of the previous close price of AU$0.10, shares in Immuron had a market capitalisation of AU$21.64m.
Where are Immuron shares listed?
Here are the trading details for Immuron:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: IMC
What kind of share is Immuron?
Based on an overall assessment of its quality, value and momentum Immuron is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Immuron share price forecast for 2024?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Immuron share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Immuron. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -36.1%.
As of the last closing price of AU$0.10, shares in Immuron were trading +5.58% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Immuron PE Ratio?
The Immuron PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Immuron?
Immuron's management team is headed by:
- Roger Aston - NEC
- Jerry Kanellos - COO
- Dan Peres - OTH
- Phillip Hains - SEC
- Ravi Savarirayan - DRC
- Stephen Anastasiou - NED
- Daniel Pollock - NED